AVE0991, a nonpeptide angiotensin-(1–7) mimic, inhibits angiotensin II–induced abdominal aortic aneurysm formation in apolipoprotein E knockout mice

AVE0991, a nonpeptide angiotensin-(1–7) mimic, has similar protective effects for cardiovascular system to Ang-(1–7). In this article, we aimed to explore the effects of AVE0991 and Ang-(1–7) on abdominal aortic aneurysm (AAA) induced by Ang II in apolipoprotein E knockout mice. The mice AAA model was established by Ang II infusion, and then mice received different treatment with saline, Ang II (1.44 mg/kg/day), different dose AVE0991 (0.58 or 1.16 μmol/kg/day), or Ang-(1–7) (400 ng/kg/min). The incidence of AAA was 76%, 48%, 28%, and 24% in the vehicle, the low-dose AVE0991, high-dose AVE0991, and the Ang-(1–7) group, respectively. In comparison with control group, AVE0991 and Ang-(1–7) treatment significantly increased smooth muscle cells and decreased macrophage accumulation, the expression levels of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor α (TNF-α), and the expression and activity of metalloproteinases 2 and 9 in mice AAA model or in human smooth muscle cells (hVSMCs). The therapeutic effects may be contributed to reduction of oxidative stress and downregulation of P38 and ERK1/2 signal pathways via Mas receptor activation, whereas the positive impacts were reversed by co-administration with the Mas antagonist A779 (400 ng/kg/min) and AVE0991 in Ang II–infused mice or in hVSMCs. Therefore, AVE0991 and Ang-(1–7) might be novel and promising interventions in the prevention and treatment of AAA. Key messages • AVE0991 dose-dependently inhibited Ang II–induced AAA formation in Apoe −/− mice. • Ang-(1–7) played the same protective role as high-dose AVE0991. • Inhibition of Mas receptor with A779 could reverse the protective effect of AVE0991. • The therapeutic effects may be contributed to reduction of oxidative stress and downregulation of P38 and ERK1/2 signal pathways via Mas receptor activation.